November 19, 2026

BE Biosol, Gates Foundation collaborate to expand access to anaemia treatment in Africa

Hyderabad, Nov 19 (TNT) : BE Biosol Private Limited, a wholly owned subsidiary of Biological E Limited, has entered into an agreement with the Gates Foundation to develop and expand access to Ferric Carboxymaltose (FCM) injection in multiple African countries.
The collaboration aims to improve access to affordable treatment for iron deficiency anaemia, which affects millions of people worldwide, particularly in low- and middle-income countries, the Hyderabad based pharmaceutical and biologics company said in a release on Thursday.
Under the agreement, the Gates Foundation will support BE Biosol in scaling up production and undertaking clinical development of the product for target markets. BE Biosol will utilise its research and development capabilities and manufacturing infrastructure to advance the programme.
The company’s manufacturing facility at Shamirpet, outskirts of the Hyderabad,  commissioned in 2018, has undergone inspections and secured approvals from several international regulatory agencies, including the US Food and Drug Administration (USFDA), Portugal’s Infarmed, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Brazil’s ANVISA.
The partnership is expected to strengthen BE Biosol’s capabilities in the global FCM market, particularly as the US and European markets move towards generic competition.
The company plans to leverage its manufacturing scale and proprietary active pharmaceutical ingredient (API) technology to develop a differentiated and cost-competitive product.
BE Biosol Managing Director Narender Mantena said the collaboration reaffirmed the company’s commitment to public health and reflected confidence in its ability to develop and manufacture technologically demanding sterile formulations at competitive costs and scale.
BE Biosol, the contract development and manufacturing organisation (CDMO) arm of Biological E, is developing a global manufacturing platform focusing on vaccines, monoclonal antibodies, antibody-drug conjugates, mRNA therapeutics and complex injectable products.
TNT TS
Share on Social Media

Leave a Reply

Your email address will not be published. Required fields are marked *